IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Aisling Capital Management LP

Q4 2018 Holdings

Filed 2019-02-08 | 12 holdings | $10.6M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Arcus Biosciences, Inc. (Rcus)(RCUS)COM03969F109$5.8M536,51354.8%
Aclaris Theraputics Inc (Acrs)(ACRS)COM00461U105$4.7M634,45544.4%
ObsEva SA (Obsv)COMH5861P103$17.6K1,386,3380.2%
Eidos Therapeutics, Inc. (Eidix)(EIDXGBP)COM28249H104$15.5K1,123,6300.1%
Avrobio, Inc. (Avro)COM05455M100$12.3K736,9980.1%
Marker Therapeutics, Inc. (Mrkr)COM57055L107$11.1K2,000,0000.1%
Biohaven Pharmaceutical Holding Company Ltd. (Bhvn)(BHVN)COMG11196105$10.2K274,5130.1%
Aeglea Biotherapeutics Inc (Agle)(AGLEUSD)COM00773J103$6.5K868,6210.1%
Verona Pharma plc (Vrna)(VRNA)COM925050106$4.3K443,5960.0%
Zosano Pharma Corporation (Zsan)COM98979H202$3.4K1,600,0000.0%
Nabriva Therapeutics plc (Nbrv)SHSG63637105$2.6K1,809,2590.0%
Sunesis Pharmaceuticals, Inc. (Snss)COM867328700$1.1K2,600,0000.0%